4.4 Review

Current Role of Prospective Monitoring and Preemptive and Prophylactic Therapy for Human Herpesvirus 6 After Allogeneic Stem Cell Transplantation

Related references

Note: Only part of the references are listed.
Article Hematology

Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation

Najla El Jurdi et al.

Summary: Prophylactic use of foscarnet in patients undergoing umbilical cord blood hematopoietic cell transplantation did not prevent HHV-6 viremia, but delayed the time to HHV-6 reactivation, increased neutrophil and platelet engraftment rates, and improved overall survival and nonrelapse mortality rates post-transplant compared to historical controls.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Article Immunology

Retrospective case analysis of antiviral therapies for HHV-6 encephalitis after hematopoietic stem cell transplantation

Danny Toomey et al.

Summary: HHV-6 encephalitis in HCT recipients is commonly treated with CMV antivirals, but combination therapy with foscarnet and ganciclovir may reduce the development of sequelae.

TRANSPLANT INFECTIOUS DISEASE (2021)

Article Infectious Diseases

Human herpesvirus 6 myelitis after chimeric antigen receptor T-cell therapy

Guy Handley et al.

Summary: This article presents a fatal case of HHV-6 myelitis following CD19-targeted chimeric antigen receptor T-cell therapy. The patient initially developed cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, which progressed to neuromuscular respiratory failure and death. Treatment with foscarnet and immunomodulating agents was ineffective in halting disease progression.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Review Virology

Human herpesvirus 6 and central nervous system disease in oncology patients: A retrospective case series and literature review

Guy Handley et al.

Summary: This study reviewed HHV-6 CNS infection in patients admitted to MD Anderson Cancer Center between March 2016 and December 2018. Among 725 patients tested for HHV-6, 19 cases (2.6%) of HHV-6 mediated CNS disease were identified, with most patients being HSCT recipients. Survival rate at 240 days post-transplant was 62%. The study also found that significant diagnostic discordance exists between testing platforms, and HHV-6 reactivation leading to CNS disease can also occur in patients receiving CAR T-cell therapy or biologic immunotherapy.

JOURNAL OF CLINICAL VIROLOGY (2021)

Article Hematology

Guidelines for Infection Prophylaxis, Monitoring and Therapy in Cord Blood Transplantation

Amanda L. Olson et al.

Summary: Cord blood transplant (CBT) has advantages as a stem cell source, but recipients are still at high risk of infectious complications. This guidance provides evidence-based recommendations for preventing and treating opportunistic infections in adult patients undergoing CBT, covering prophylaxis, virus monitoring, infection therapy, and the role of medications like letermovir. Practice recommendations are also given in data-scarce scenarios, including the duration of antimicrobial prophylaxis.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Review Pharmacology & Pharmacy

Current understanding of human herpesvirus 6 (HHV-6) chromosomal integration

Giulia Aimola et al.

ANTIVIRAL RESEARCH (2020)

Article Hematology

Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome

Raffaella Greco et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)

Review Microbiology

Laboratory and Clinical Aspects of Human Herpesvirus 6 Infections

Henri Agut et al.

CLINICAL MICROBIOLOGY REVIEWS (2015)

Review Virology

Classification of HHV-6A and HHV-6B as distinct viruses

Dharam Ablashi et al.

ARCHIVES OF VIROLOGY (2014)

Article Hematology

Early Human Herpesvirus Type 6 Reactivation after Allogeneic Stem Cell Transplantation: A Large-Scale Clinical Study

Remy Dulery et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)

Review Virology

Chromosomally integrated human herpesvirus 6: questions and answers

Philip E. Pellett et al.

REVIEWS IN MEDICAL VIROLOGY (2012)

Letter Hematology

Low-Dose Foscarnet Preemptive Therapy for Cytomegalovirus Viremia after Haploidentical Bone Marrow Transplantation

Hengxiang Wang et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)

Article Neurosciences

Efficacy of antiviral compounds in human herpesvirus-6-infected glial cells

Nahid Akhyani et al.

JOURNAL OF NEUROVIROLOGY (2006)

Article Clinical Neurology

Human herpesvirus 6 limbic encephalitis after stem cell transplantation

MS Wainwright et al.

ANNALS OF NEUROLOGY (2001)